Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy

References

• Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W. and Tubiana, M. (1971) "Report of the Committee on Hodgkin's Disease Staging Classification", Cancer Research, 31, 1860— 1861.
   Google Scholar
• Hagemeister, F.B., Fuller, L.M., Sullivan, J.A., Johnston, D., North, L., Butler, J.J., et al. (1982) "Treatment of patients with stages I and II nonmediastinal Hodgkin's disease", Cancer, 50, 2307— 2313.
   Google Scholar
• Leslie, N.T., Mauch, P.M. and Hellman, S. (1985) "Stage IA to JIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency", Cancer, 55, 2072 — 2078.
   Google Scholar
• Sutcliffe, S.B., Gospodarowicz, M.K., Bergsagel, D.E., Bush, R.S., Alison, RE., Bean, HA., et al. (1985) "Prognostic groups for management of localized Hodgkin's disease", Journal of Clinical Oncology, 3, 393–401.
   PubMed Web of Science ®Google Scholar
• Cornbleet, MA., Vitolo, U., Ultmann, J.E., Golomb, H.M., Oleske, D., Griem, ML., et al. (1985) "Pathologic stages IA and IIA Hodgkin's disease: Results of treatment with radiotherapy alone (1968-1980) ", Journal of Clinical Oncology, 3,758–768.
   Google Scholar
• Carde, P., Burgers, J.M.V., Henry-Amar, M., Hayat, M., Sizoo, W., Van der Schueren, E., et al. (1988) "Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors", Journal of Clinical Oncology, 6, 239 — 252.
   Google Scholar
• Farah, R., Ultmann, J., Griem, M., Golomb, H., Kalokhe, U., Desser, R., et al. (1988) "Extended mantle radiation therapy for pathologic Stage I and II Hodgkin's disease", Journal of Clinical Oncology, 6, 1047 — 1052.
   Google Scholar
• Backstrand, K.H., Ng, AK., Takvorian, R.W., Jones, EL., Fisher, D.C., Molnar-Griffin, B.J., et al. (2001) "Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease", Journal of Clinical Oncology, 19, 736–741.
   PubMed Web of Science ®Google Scholar
• Mauch, P., Tarbell, N., Weinstein, H., Silver, B., Goffman, T., Osteen, R., et al. (1988) "Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation", Journal of Clinical Oncology, 6, 1576— 1583.
   Google Scholar
• Gospodarowicz, M.K., Sutcliffe, S.B., Bergsagel, D.E. and Chua, T. (1992) "Radiation therapy in clinical stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group", European Journal of Cancer, 11, 1841–1846.
   Google Scholar
• Carde, P., Hagenbeek, A., Hayat, M., Monconduit, M., Thomas, J., Burgers, M.J.V., et al. (1993) "Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group", Journal of Clinical Oncology, 11, 2258— 2272.
   Google Scholar
• Noordijk, EM., Carde, P., Mandard, A.M., Mellink, WA., Monconduit, M., Eghbali, H., et al. (1994) "Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease", Annals of Oncology, 5\(Supp1.2), 107 — 112.
   Google Scholar
• Duhmke, E., Franklin, J., Pfreundschuh, M., Sehlen, S., Willich, N., Ruhl, U., et al. (2001) "Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone", Journal of Clinical Oncology, 19, 2905–2914.
   Google Scholar
• Haybittle, J.L., Hayhoe, F.G., Easterling, Mi., Jelliffe, A.M., Bennett, M.H., Vaughan-Hudson, G., et al. (1985) "Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index", Lancet, 1, 967–972.
   PubMed Web of Science ®Google Scholar
• Horwich, A., Easton, D., Nogueira-Costa, R., Liew, K.H., Colman, M. and Peckham, M.J. (1986) "An analysis of prognostic factors in early stage Hodgkin's disease", Radiotherapy Oncology, 7, 95–106.
   Google Scholar
• Tubiana, M., Henry-Amar, M., Carde, P., Burgers, J.M., Hayat, M., Van der Schueren, E., et al. (1989) "Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964— 1987", Blood, 73, 47–56.
   PubMed Web of Science ®Google Scholar
• Cosset, J.M., Ferme, C., Henry-Amar, M. and Carde, P. (1999) "The role of radiotherapy for limited stage Hodgkin's disease in 1999: limitations and perspectives", Cancer Radiotherapy, 3, 112 — 118.
   PubMedGoogle Scholar
• Verger, E., Easton, D., Brada, M., Duchesne, G. and Horwich, A. (1988) "Radiotherapy results in laparotomy-staged Hodgkin's disease", Clinical Radiology, 39, 428–431.
   PubMed Web of Science ®Google Scholar
• Tubiana, M., Henry-Amar, M., Hayat, M., Burgers, M., Qasim, M., Somers, R., et al. (1984) "The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy", International Journal of Radiation Oncology Biology Physics, 10, 197 — 210.
   Google Scholar
• Crnkovich, Mi., Leopold, K., Hoppe, R.T. and Mauch, P. (1987) "Stage I to JIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy", Journal of Clinical Oncology, 5, 1041–1049.
   Google Scholar
• Specht, L., Nordentoft, A.M., Cold, S., Toffner Clausen, N. and Nissen, N. (1988) "Tumor burden as the most important prognostic factor in early-stage Hodgkin's disease: relations to other prognostic factors and implications for choice of treatment", Cancer, 61, 1719 — 1727.
   Google Scholar
• Henry-Amar, M., Meerwaldt, J., Carde, P., Noordijk, EM., Thomas, J., Eghbali, H., et al. (2001) "The EORTC treatment strategy in Hodgkin's lymphoma (HL): A 4-decade experience", Leukemia and Lymphoma, 42\(Suppl. 2), 54.
   Google Scholar
• Hasenclever, D. and Diehl, V. (1998) "A prognostic score for advanced Hodgkin's disease", New England Journal of Medicine, 339, 1506–1514.
   PubMed Web of Science ®Google Scholar
• Franklin, J., Paulus, U., Lieberz, D., Breuer, K., Tesch, H. and Diehl, V. (2000) "Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients?", Annals of Oncology, 11, 617 — 623.
   Google Scholar
• Nadali, G., Tavecchia, L., Zanolin, E., Bonfante, V., Viviani, S., Camerini, E., et al. (1998) "Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome", Blood, 91, 3011–3016.
   PubMed Web of Science ®Google Scholar
• Axdorph, U., Sjoberg, J., Grimfors, G., Landgren, 0., Porwit-MacDonald, A. and Björkholm, M. (2000) "Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease", Annals of Oncology, 11, 1405 — 1411.
   Google Scholar
• Enblad, G., Sundstrom, C., Gronowitz, S. and Glimelius, B. (1995) "Serum levels of interleulcin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis", Annals of Oncology, 6, 65— 70.
   Google Scholar
• Sarris, A.H., Kliche, K.O., Pethambaram, P., Preti, A., Tucker, S., Jackow, C., et al. (1999) "Interleulcin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival", Annals of Oncology, 10, 433–440.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos, T.P., Nadali, G., Angelopoulou, M.K., Siakan-taris, M.P., Dimopoulou, M.N., Kontopidou, F.N., et al. (2001) "Serum interleulcin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma", Haematologica, 86, 274 — 281.
   Google Scholar
• Viviani, S., Notti, P., Bonfante, V., Verderio, P., Valagussa, P. and Bonadonna, G. (2000) "Elevated pretreatment serum levels of I1-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience", Medical Oncology, 17, 59–63.
   PubMed Web of Science ®Google Scholar
• Bohlen, H., Kessler, M., Sextro, M., Diehl, V. and Tesch, H. (2000) "Poor clinical outcome of patients with Hodgkin's disease and elevated interleulcin-10 serum levels. Clinical significance of inter-leulcin-10 serum levels for Hodgkin's disease", Annals of Hematol-ogy, 79, 110–113.
   PubMed Web of Science ®Google Scholar
• Salgami, E.V., Efstathiou, S.P., Vlachalcis, V., Sekara, E.V., Syrigos, K.N. and Roussou, P.P. (2002) "High pretreatment interleulcin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma", Haematologia (Budap), 32, 377 — 387.
   Google Scholar
• Rassidakis, G.Z., Medeiros, L.J., Vassilakopoulos, T.P., Viviani, S., Bonfante, V., Nadali, G., et al. (2002) "Bc1-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens", Blood, 100, 3935–3941.
   PubMed Web of Science ®Google Scholar
• Garcia, J.F., Camacho, FT., Morente, M., Fraga, M., Montalban, C., Alvaro, T., et al. (2003) "Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays", Blood, 101, 681 — 689.
   Google Scholar
• Rassidalcis, G.Z., Medeiros, Li., McDonnell, Ti., Viviani, S., Bonfante, V., Nadali, G., et al. (2002) "Bax expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: Correlation with clinical outcome", Clinical Cancer Research, 8, 488–493.
   PubMed Web of Science ®Google Scholar
• Dukers, D.F., Meijer, C.J.L.M., ten Berge, R.L., Vos, W., Ossenkoppele, G.J. and Oudejans, J.J. (2002) "High numbers of active caspase 3-positive Reed Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin's disease predict favorable clinical outcome", Blood, 100, 36–42.
   PubMed Web of Science ®Google Scholar
• Rassidalcis, G.Z., Medeiros, Li., Drakos, E., Vassilakopoulos, T.P., Viviani, S., Bonfante, V., et al. (2002) "Activated caspase-3 in Hodgkin and Reed-Sternberg cells (HRS) predicts a poorer prognosis in patients with classical Hodgkin's disease (HD) treated with ABVD or equivalent regimens", Blood, 100(11), 349a (Abstract).
   Google Scholar
• Weber-Nordt, R.M., Henschler, R., Schott, E., Wehinger, J., Behringer, D., Mertelsmann, R., et al. (1996) "Interleukin-10 increases Bc1-2 expression and survival in primary human CD34 + hematopoietic progenitor cells", Blood, 88, 2549 — 2558.
   Google Scholar
• Taga, K., Cherney, B. and Tosato, G. (1993) "IL-10 inhibits apoptotic cell death in human T cells starved of IL-2", International Immunology, 5, 1599–1608.
   Web of Science ®Google Scholar
• Brunetti, M., Martelli, N., Colasante, A., Piantelli, M., Musiani, P. and Aiello, F.B. (1995) "Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes", Blood, 86, 4199–4205.
   Google Scholar
• Ohshima, K., Suzumiya, J., Akamatu, M., Takeshita, M. and Kikuchi, M. (1995) "Human and viral interleulcin-10 in Hodgkin's disease, and its influence on CD4 + and CD8 + T lymphocytes", International Journal Cancer, 62, 5 — 10.
   Google Scholar
• Herbst, H., Foss, H.D., Samol, J., Araujo, I., Klotzbach, H., Krause, H., et al. (1996) "Frequent expression of interleulcin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease", Blood, 87, 2918–2929.
   PubMed Web of Science ®Google Scholar
• Rueda, A., Alba, E., Ribelles, N., Sevilla, I., Ruiz, I. and Miramon, J. (1997) "Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: a pilot study", Journal of Clinical Oncology, 15, 1118–1122.
   PubMed Web of Science ®Google Scholar
• Straus, DJ., Yahalom, J., Zelenetz, A.D., Qin, J., Myers, J., Moskowitz, C.H., et al. (2001) "Results of a prospective rando-mized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD + radiation therapy for early stage non bulky Hodgkin's disease", Blood, 98, 769a [Abstract].
   Google Scholar
• Rappaport, H., Berard, C.W., Butler, J.J., Dorfman, R.F., Lukes, R.J. and Thomas, L.B. (1971) "Report of the committee on histopathological criteria contributing to staging of Hodgkin's disease", Cancer Research, 31, 1864 — 1865.
   Google Scholar
• Stein, H., Mann, R., Delsol, G., Poppema, S., Pileri, S., Jaffe, ES., et al. (2001) Classical Hodgkin lymphoma. In: Tumors of the haematopoietic and lymphoid tissues. Pathology and Genetics. World Health Organization Classification of Tumors, edited by E. Jaffe, N. Harris, H. Stein and J. Vardiman. Pp 244–253. Lyon, France: IARC Press.
   Google Scholar
• Sarris, A.H. (1997) "Prognostic factors in early-stage Hodgkin's disease", Journal of Clinical Oncology, 15, 411 — 412.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos, T.P., Nadali, G., Angelopoulou, M.K., Siakan-taris, M.P., Dimopoulou, M.N., Kontopidou, F.N., et al. (2002) "The prognostic significance of /32-microglobulin in patients with Hodgkin's lymphoma", Haematologica, 87, 701–708.
   PubMed Web of Science ®Google Scholar
• Kaplan, E. and Meier, P. (1958) "Nonparametric estimation from incomplete observations", Journal of American Statistical Associa-tion, 53, 457 — 481.
   Web of Science ®Google Scholar
• Peto, R., Pike, MC., Armitage, P., Breslow, N.E., Cox, DR., Howard, S.V., et al. (1977) "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples", Br. J. Cancer, 35, 1— 39.
   Web of Science ®Google Scholar
• Cox, D.R. (1972) "Regression models and life tables (with discussion)", Journal Royal Statistical Society, 34, 187–220.
   Google Scholar
• Angelopoulou, M.K., Vassilakopoulos, T.P., Siakantaris, M.P., Kontopidou, F.N., Boussiotis, V.A., Papavassiliou, C., et al. (2000) "EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease", Leukemia and Lymphoma, 37, 131–143.
   Google Scholar
• Santoro, A., Bonfante, V., Viviani, S., Devizzi, L., Zanini, M., Soncini, F., et al. (1996) "Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease (HD)", Proceedings of the American Society of Clinical Oncology, 15, 415 (Abstract).
   Google Scholar
• Vassilakopoulos, T.P., Angelopoulou, M.K., Siakantaris, M.P., Kontopidou, F.N., Dimopoulou, M.N., Kokoris, S.I., et al. (2004) "Combination chemotherapy plus low dose involved field radiation for early clinical stage Hodgkin's lymphoma", International Journal of Radiation Oncology Biology Physics (in press).
   Google Scholar
• Ruiz-Arguelles, G.J., Gomez-Almaguer, D. and Apreza-Molina, M.G. (1997) "Chemotherapy alone may be an efficient alternative in the treatment of early stage Hodgkin's disease if optimal radio-therapy is not available", Leukemia and Lymphoma, 27, 179–183.
   Google Scholar
• Dukers, D.F., Jaspars, L.H., Vos, W., Oudejans, J.J., Hayes, D., Cillessen, S., et al. (2000) "Quantitative immunohistochemical analysis of cytolcine profiles in Epstein-Barr virus-positive and - negative cases of Hodgkin's disease", Journal of Pathology, 190, 143–149.
   Google Scholar
• Rassidalcis, G.Z., Medeiros, Li., Nadali, G., Viviani, S., Bonfante, V., Vassilakopoulos, T.P., et al. (2001) "Expression of interleulcin-10 (IL-10) in Hodgkin's disease (HD): Pathologic and clinical associations", Blood, 98(11-part 1), 599a (Abstract).
   Google Scholar